StemCell Therapy

Equities research analysts forecast that BIO-TECHNE Corp (NASDAQ:TECH) will report earnings of $1.14 per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for BIO-TECHNEs earnings. The lowest EPS estimate is $1.12 and the highest is $1.16. BIO-TECHNE reported earnings of $1.06 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 7.5%. The company is expected to report its next quarterly earnings report on Tuesday, February 4th.

On average, analysts expect that BIO-TECHNE will report full-year earnings of $4.94 per share for the current year, with EPS estimates ranging from $4.85 to $5.04. For the next year, analysts expect that the business will post earnings of $5.77 per share, with EPS estimates ranging from $5.45 to $6.07. Zacks earnings per share averages are an average based on a survey of research analysts that cover BIO-TECHNE.

BIO-TECHNE (NASDAQ:TECH) last posted its earnings results on Tuesday, October 29th. The biotechnology company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.14. The firm had revenue of $183.24 million during the quarter, compared to analysts expectations of $179.38 million. BIO-TECHNE had a return on equity of 13.36% and a net margin of 12.68%. The firms revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.98 earnings per share.

Several equities research analysts recently weighed in on TECH shares. TheStreet upgraded BIO-TECHNE from a c+ rating to a b- rating in a research note on Wednesday, November 27th. ValuEngine cut BIO-TECHNE from a buy rating to a hold rating in a research note on Tuesday, December 3rd. BidaskClub upgraded BIO-TECHNE from a sell rating to a hold rating in a research note on Tuesday, September 17th. Zacks Investment Research cut BIO-TECHNE from a hold rating to a sell rating in a research note on Saturday, November 2nd. Finally, Stifel Nicolaus started coverage on BIO-TECHNE in a research note on Thursday, November 14th. They issued a buy rating and a $235.00 price objective for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the companys stock. The stock has an average rating of Hold and a consensus target price of $224.50.

In other BIO-TECHNE news, CEO Charles R. Kummeth sold 703 shares of the businesss stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $222.01, for a total value of $156,073.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Roeland Nusse sold 8,347 shares of the businesss stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $219.33, for a total value of $1,830,747.51. Following the completion of the sale, the director now owns 15,721 shares of the companys stock, valued at approximately $3,448,086.93. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,271 shares of company stock valued at $7,503,700. 4.20% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. raised its stake in shares of BIO-TECHNE by 97.1% during the second quarter. Invesco Ltd. now owns 1,064,196 shares of the biotechnology companys stock worth $221,874,000 after purchasing an additional 524,216 shares during the last quarter. Nuveen Asset Management LLC raised its stake in shares of BIO-TECHNE by 6,323.4% during the second quarter. Nuveen Asset Management LLC now owns 126,091 shares of the biotechnology companys stock worth $26,289,000 after purchasing an additional 124,128 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of BIO-TECHNE by 229.8% during the second quarter. BNP Paribas Arbitrage SA now owns 47,344 shares of the biotechnology companys stock worth $9,871,000 after purchasing an additional 32,989 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of BIO-TECHNE by 3.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 951,301 shares of the biotechnology companys stock worth $186,141,000 after purchasing an additional 31,700 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. raised its stake in shares of BIO-TECHNE by 20.2% during the third quarter. Candriam Luxembourg S.C.A. now owns 129,857 shares of the biotechnology companys stock worth $25,000 after purchasing an additional 21,840 shares during the last quarter. Institutional investors own 93.11% of the companys stock.

TECH stock traded down $5.29 during trading on Friday, hitting $213.02. 122,699 shares of the companys stock were exchanged, compared to its average volume of 117,811. The business has a 50-day moving average price of $212.32 and a two-hundred day moving average price of $204.52. The stock has a market capitalization of $8.22 billion, a price-to-earnings ratio of 56.06, a PEG ratio of 4.61 and a beta of 1.23. BIO-TECHNE has a 52-week low of $132.75 and a 52-week high of $222.87. The company has a current ratio of 4.44, a quick ratio of 3.41 and a debt-to-equity ratio of 0.47.

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 22nd. Shareholders of record on Friday, November 8th were paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.60%. The ex-dividend date was Thursday, November 7th. BIO-TECHNEs dividend payout ratio is currently 33.68%.

BIO-TECHNE Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

Featured Article: What causes a recession?

Get a free copy of the Zacks research report on BIO-TECHNE (TECH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.

See the rest here:
$1.14 Earnings Per Share Expected for BIO-TECHNE Corp (NASDAQ:TECH) This Quarter - Riverton Roll

This entry was posted on December 30, 2019 at 4:12 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |